<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03884777</url>
  </required_header>
  <id_info>
    <org_study_id>CIC1429</org_study_id>
    <nct_id>NCT03884777</nct_id>
  </id_info>
  <brief_title>Incidence and Risk of Influenza in Myasthenic Patients</brief_title>
  <official_title>Incidence and Risk of Influenza in Myasthenic Patients Hospitalized in Intensive Care</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre d'Investigation Clinique et Technologique 805</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre d'Investigation Clinique et Technologique 805</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Upper respiratory infection , including influenza, may exacerbate the symptoms of myasthenia
      gravis (MG), which is an autoimmune disease that causes muscle weakness and, in some cases,
      can precipitate a myasthenic crisis

      In the present study, we investigated the incidence and risk factors of influenza infection
      on in myasthenia gravis patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a descriptive study. The data will be analyzed retrospectively . Inclusion of 416
      cases of influenza in myasthenic patients treated in the intensive care unit of Garches
      Hospital between January 1, 2009 and December 31, 2017.

      Patients who meet the inclusion and non inclusion criteria and do not object to participate
      in the study will be collected in a database for analysis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2009</start_date>
  <completion_date type="Actual">December 31, 2017</completion_date>
  <primary_completion_date type="Actual">December 31, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of influenza in myasthenic patient in crisis</measure>
    <time_frame>between January 1, 2009 and December 31, 2017.</time_frame>
    <description>Number of influenza cases in myasthenic patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Risk factors for poor outcomes</measure>
    <time_frame>between January 1, 2009 and December 31, 2017.</time_frame>
    <description>To identify risk factors for severe influenza in myasthenic patients</description>
  </secondary_outcome>
  <enrollment type="Actual">400</enrollment>
  <condition>Myasthenic Crisis</condition>
  <condition>Upper Respiratory Infection</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Inclusion of 416 cases of myasthenic patients treated in the intensive care unit of Garches
        Hospital between January 1, 2009 and December 31, 2017.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men or women over the age of 18.

          -  Myasthenic patients hospitalized in intensive care.

          -  Patients with confirmed influenza infection

        Exclusion Criteria:

          -  Age &lt;18 years,

          -  Other neuromuscular diseases,

          -  Patient opposing the use of his data
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Rania BOUNAB, Dr</last_name>
    <role>Study Director</role>
    <affiliation>Raymond Poincaré Hospital</affiliation>
  </overall_official>
  <results_reference>
    <citation>Petrova VN, Russell CA. The evolution of seasonal influenza viruses. Nat Rev Microbiol. 2018 Jan;16(1):60. doi: 10.1038/nrmicro.2017.146. Epub 2017 Nov 7.</citation>
    <PMID>29109554</PMID>
  </results_reference>
  <results_reference>
    <citation>Tackenberg B, Schneider M, Blaes F, Eienbröker C, Schade-Brittinger C, Wellek A, Deschauer M, Eickmann M, Klenk HD, Müller HH, Sommer N. Acetylcholine Receptor Antibody Titers and Clinical Course after Influenza Vaccination in Patients with Myasthenia Gravis: A Double-Blind Randomized Controlled Trial (ProPATIent-Trial). EBioMedicine. 2018 Feb;28:143-150. doi: 10.1016/j.ebiom.2018.01.007. Epub 2018 Jan 10.</citation>
    <PMID>29337134</PMID>
  </results_reference>
  <results_reference>
    <citation>Friman G, Schiller HH, Schwartz M. Distubed neuromuscular transmission in viral infections. Scand J Infect Dis. 1977;9(2):99-103.</citation>
    <PMID>197596</PMID>
  </results_reference>
  <results_reference>
    <citation>Rościszewska D, Bluszcz M, Kurek H. [Antibodies for DNA and RNA viruses in the serum of myasthenia patients. Preliminary report]. Neurol Neurochir Pol. 1981 Sep-Dec;15(5-6):541-4. Polish.</citation>
    <PMID>6281675</PMID>
  </results_reference>
  <verification_date>December 2017</verification_date>
  <study_first_submitted>January 16, 2019</study_first_submitted>
  <study_first_submitted_qc>March 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 21, 2019</study_first_posted>
  <last_update_submitted>March 20, 2019</last_update_submitted>
  <last_update_submitted_qc>March 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza A virus</keyword>
  <keyword>myasthenia gravis</keyword>
  <keyword>neurocritical care clinical</keyword>
  <keyword>neuromuscular disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Tract Infections</mesh_term>
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

